Pulmonary Hypertension

Pulmonary arterial hypertension (PAH) is a diverse spectrum of diseases characterized by elevated pressures and progressive occlusion of the pulmonary arteries, leading to serious hemodynamic abnormality, right heart failure, and premature death with an estimated 5-year survival rate of 50%. PAH remains a highly fatal syndrome despite recent advancements in its treatment. Current therapies have shown promise in potentially providing improved treatment, but are not specific for lung vessels; their usage is limited by their tendency to lower pressure in all blood vessels and cause side effects or toxicity in other organs.

CAR peptide addresses an unmet need in PAH patient care by providing a targeting technology that makes existing PAH therapies more effective and pulmonary-specific, while reducing unwanted side effects of systemic therapies. Simple co-administration of CAR with systemic vasodilators selectively enhances the pulmonary vascular effects of the therapy by reducing right ventricular systolic pressure without also reducing systemic arterial pressure. CAR fills an important niche in PAH care by enabling pulmonary arterial selective drug delivery, an important advancement in PAH targeted therapy.

VBS is currently conducting combination therapy experiments with CAR liposome. We will perform studies on co-administration of CAR peptide with different combinations of PH treatments. VBS is also developing CAR conjugated liposome therapies for pulmonary hypertension. These CAR targeted liposomes can be loaded with combinations of potent pulmonary hypertension drugs for selective delivery and minimal side effects.

Next Steps:

DISCLAIMER: The material provided on this site is strictly for informational purposes. Do not use this site as a substitute for medical care or medical advice. Please consult with your physician or other medical care provider regarding any medical questions you may have.

Products & Services